KRAS and colorectal cancer: According to Yun et al., colorectal cancer cells with KRAS and BRAF mutations have a constitutively activated GLUT1 and enhanced glycolysis, in contrast with cells with mutations in PIK3CA (the catalytic part of PI3K) [44].